For Better User Experience Please Use Potrait Mode.
OncoStem Diagnostics has launched CanAssist-Breast, a test which can reportedly predict the likelihood of cancer returning by analysing samples of a patient’s tumour through a machine learning-based algorithm.
November 05, 2018
OncoStem Diagnostics has developed a promising diagnostic test that can spare breast cancer patients from unnecessary chemotherapy. By analysing the patient’s tumour biology, CanAssist-Breast identifies patients at ‘low-risk’ or ‘high-risk’ for recurrence to assess the benefit of adding chemotherapy to their treatment.
November 01, 2018
In many cases, early detection can go a long way in saving the lives. And Bengaluru-based breast cancer screening startup, OncoStem, is doing just that.
October 25, 2018
When should a breast cancer patient go for chemotherapy? Studies have shown that the rate of recurrence in early-stage breast cancer patients is low. This indicates that a vast majority of these patients receive little to no benefit from the addition of chemotherapy to their treatment regimen.
October 09, 2018
The benefit that early-stage patients receive from chemotherapy is usually low. Since most early-stage patients do well without chemotherapy, this makes accurate risk prediction an all-important prerequisite for effective treatment.
September 07, 2018
While machine learning has already proven its worth in many fields, be it travel, logistics or online shopping, health care is emerging as a sector where it is expected to be a game changer
August 11, 2018
For Dr Manjiri Bakre, 48, founding OncoStem Diagnostics was driven by a personal experience. Within two years of diagnosis a close friend passed away at 30 due to breast cancer
July 10, 2018
NEW INDIAN EXPRESS
Thirty-one-year-old Marie would have undergone chemotherapy but for Dr Manjiri Bakre and her OncoStem’s CanAssist-Breast test. The test showed that the newly married woman belonged
July 08, 2018
We have come a long way from the era when surgery was the only treatment modality for breast cancer and has reached several milestones akin to radiation therapy, chemotherapy
June 11, 2018
Sequoia Capital and Artiman Ventures-backed OncoStem Diagnostics predicts cancer recurrence in a patient through its flagship product, CanAssist. While its current focus
June 09, 2018
A close friend of Dr. Manjiri Bakre's -- a cell biology veteran with significant experience in cancer biology and drug discovery -- was diagnosed with early-stage breast cancer
June 01, 2018
May 26, 2018
OncoStem Diagnostics, a Bengaluru- based oncology-focused startup, has raised $6 million in a funding round led by Sequoia India. The firm is focused on personalised cancer treatment
May 21, 2018
Dr Manjiri Bakre's OncoStem is revolutionising breast cancer treatment in India with a test that is faster AND cheaper than what is currently available in Europe and the US.
September 27, 2017
OncoStem Diagnostics announces the launch of its flagship product
November 30, 2016
THE ECONOMIC TIMES
"Today in India over 90% of breast cancer patients go for chemotherapy to avoid recurrence however if you are a stage 1 cancer patient you might not have to go through
October 04, 2016
ABSICON PRESS RELEASE
OncoStem Diagnostics participated in ABSICON 2016, a Breast Cancer focused surgical oncology meeting held from July 1st-3rd at Hotel ITC Gardenia, Bangalore. Dr. Manjiri Bakre gave
July 04, 2016